{"id":3848,"date":"2018-12-11T13:04:34","date_gmt":"2018-12-11T13:04:34","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/"},"modified":"2018-12-11T13:04:34","modified_gmt":"2018-12-11T13:04:34","slug":"nanexa-valjer-substans-for-produktprojektet-nex-18","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/","title":{"rendered":"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<p><span>Nanexa har p\u00e5b\u00f6rjat den prekliniska utvecklingen av NEX-18 och har nu genomf\u00f6rt en teknisk utv\u00e4rdering av 5-azacitidine i bolagets PharmaShell\u00ae-process. Utv\u00e4rderingen visar tydligt att PharmaShell\u00ae\u00a0belagd 5-azacitidine ger en l\u00e5ngsammare uppl\u00f6sning av substansen vid\u00a0in vitro-uppl\u00f6sningsf\u00f6rs\u00f6k, vilket m\u00f6jligg\u00f6r att skapa en dep\u00e5beredning av substansen som \u00e4r m\u00e5let f\u00f6r projektet.<\/span><\/p>\n<p><span>5-azacitidine anv\u00e4nds idag f\u00f6r behandling av b\u00e5de myelodysplastiskt syndrom (MDS) och akut myeloid leukemi (AML) och \u00e4r den aktiva substansen i produkten Vidaza som marknadsf\u00f6rs av Celgene. M\u00e5let med NEX-18 \u00e4r att utveckla en f\u00f6rb\u00e4ttrad produkt med f\u00f6rl\u00e4ngd fris\u00e4ttningsprofil som kan ers\u00e4tta dagens behandling och som dessutom erh\u00e5ller patentskydd d\u00e5 den formuleras tillsammans med Nanexas PharmaShell\u00ae-teknologi.<\/span><\/p>\n<p><span>Dagens behandling best\u00e5r av upprepade behandlingscykler med sju dagliga injektioner av Vidaza f\u00f6ljt av 21 dagar utan behandling, medan det \u00e4r m\u00e5let att en injektion av NEX-18 ska r\u00e4cka f\u00f6r hela 28-dagarscykeln. Denna enstaka injektion kommer med hj\u00e4lp av PharmaShell\u00ae\u00a0kunna f\u00f6rl\u00e4nga tiden som den aktiva substansen finns tillg\u00e4nglig i blodomloppet och har genom detta potential att, f\u00f6rutom att f\u00f6renkla behandlingen avsev\u00e4rt, ge en mer effektiv cancerbehandling och samtidigt ge en m\u00f6jlighet att reducera biverkningarna.<\/span><\/p>\n<p><span>F\u00f6retagets VD David Westberg kommenterar:<\/span><\/p>\n<p><span>\u201d\u00c4ven fast dessa resultat var v\u00e4ntade f\u00f6r oss \u00e4r det gl\u00e4djande att vi nu har erh\u00e5llit de verifierande resultaten som kr\u00e4vdes f\u00f6r att kunna v\u00e4lja aktiv substans till NEX-18- projektet. 5-azacitidine \u00e4r dessutom den substans som vi ser mest potential i.<\/span><\/p>\n<p><span>Vi kommer nu g\u00e5 vidare med optimering av processen och planering och genomf\u00f6rande av in vivo-f\u00f6rs\u00f6k med PharmaShell\u00ae-belagd 5-azacitidine. Vi bed\u00f6mer att NEX-18-produkten har stora m\u00f6jligheter; dels genom att f\u00f6rb\u00e4ttra en redan fungerade behandling och dels som basbehandling tillsammans med en del av de nya produkter som f\u00f6rv\u00e4ntas introduceras p\u00e5 marknaden.\u201d<\/span><\/p>\n<p><span>F\u00f6r mer information kontakta:<br \/>David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0Telefon: 0709 -42 83 03<br \/>E-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/p>\n<p><span>Om Nanexa AB (publ)<br \/>Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/mb.cision.com\/Main\/12591\/2697530\/961266.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">L\u00e4s som pdf<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n<p>Nanexa har p\u00e5b\u00f6rjat den prekliniska utvecklingen av NEX-18 och har nu genomf\u00f6rt en teknisk utv\u00e4rdering av 5-azacitidine i bolagets PharmaShell\u00ae-process. Utv\u00e4rderingen visar tydligt att PharmaShell\u00ae\u00a0belagd 5-azacitidine ger en l\u00e5ngsammare uppl\u00f6sning av substansen vid\u00a0in vitro-uppl\u00f6sningsf\u00f6rs\u00f6k,<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3848","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa har p\u00e5b\u00f6rjat den prekliniska utvecklingen av NEX-18 och har nu genomf\u00f6rt en teknisk utv\u00e4rdering av 5-azacitidine i bolagets PharmaShell\u00ae-process. Utv\u00e4rderingen visar tydligt att PharmaShell\u00ae\u00a0belagd 5-azacitidine ger en l\u00e5ngsammare uppl\u00f6sning av substansen vid\u00a0in vitro-uppl\u00f6sningsf\u00f6rs\u00f6k,L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-substans-for-produktprojektet-nex-18\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-substans-for-produktprojektet-nex-18\\\/\",\"name\":\"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2018-12-11T13:04:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-substans-for-produktprojektet-nex-18\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-substans-for-produktprojektet-nex-18\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-valjer-substans-for-produktprojektet-nex-18\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18 - Nanexa AB","og_description":"Nanexa har p\u00e5b\u00f6rjat den prekliniska utvecklingen av NEX-18 och har nu genomf\u00f6rt en teknisk utv\u00e4rdering av 5-azacitidine i bolagets PharmaShell\u00ae-process. Utv\u00e4rderingen visar tydligt att PharmaShell\u00ae\u00a0belagd 5-azacitidine ger en l\u00e5ngsammare uppl\u00f6sning av substansen vid\u00a0in vitro-uppl\u00f6sningsf\u00f6rs\u00f6k,L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/","name":"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2018-12-11T13:04:34+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-valjer-substans-for-produktprojektet-nex-18\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa v\u00e4ljer substans f\u00f6r produktprojektet NEX-18"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}